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SUMMARY 
The formation of a ‘tumor –associated vasculature’, a process referred to as tumor 
angiogenesis, is a stromal reaction specific for tumor angiogenesis. Angiogenesis, the 
development of new blood  vessels from the existing vasculature, is important for normal 
developmental process. Angiogenesis is an essential step for the progression of solid 
tumors. Uncontrolled angiogenesis is a major contributor to a number of disease states 
such as cancer, inflammatory disorders, Obesity, asthma, diabetes, multiple sclerosis, 
AIDS, bacterial infections, autoimmune diseases, endometriosis. It is also considered a 
key step in tumor growth, invasion and metastasis. Thus anti-angiogenic therapy is one 
of the most promising approaches to control tumor growth. Angiogenesis is required for 
proper nourishment and removal of metabolic wastes from tumor sites. Angiogenesis 
may be a relevant target to inhibit tumor progression. The anti-angiogenic molecules 
reported to date many are plant compounds, peptides, chemokines, cytokines, 
nanoparticles, siRNA, Flavonoids and Chalcones, monoclonal antibodies, soluble 
receptors, to vascular growth factors and growth factor receptors, soluble receptors and 
fragments derived from extracellular matrix proteins. Therefore, modulation of 
angiogenesis is considered as therapeutic strategies of great importance for human 
health. 
Numerous bioactive compounds from plant sources and other antiangiogenic 
compounds are recently tested for their antiangiogenic potential. Those compounds 
inhibits angiogenesis and metastasis through regulation of multiple signaling pathways. 
Those antiangiogenic compounds regulate the expression of VEGF, MMPs, EGFR, and 
inhibit NFkB, PI-3K/Akt, ERK signaling pathways, there by causing strong anti-
angiogenic effects. Thus, anti-angiogenic compounds are emerging as leading molecules 
among the plethora of compounds with anti-angiogenic activity. 
This review article describes the latest development using anti-angiogenic inhibitors to 
down regulate various angiogenic and tumor –associated factors, both in biological 
assays and in animal disease models. The majority of research efforts are currently 
focused on understanding gene function, as well as proof-of- concept for antiagiogenesis 
compounds mediated anti-angiogenesis process. 
In this article, we will review some of these molecules particularly from plant based 
sources and discuss their mechanism of action and their potential therapeutic use as 
anticancer agents in humans.  
Key words: Tumor angiogenesis, Vascular endothelial growth factor, Cancer, Bioactive compounds, 
Peptides, Antibodies,  Nanoparticles, Flavonoids, Chalcones  
Manoj G Tyagi et al. Pathophysiology of Angiogenesis and Novel Angiomodulators from Plant Sources for Therapeutic Purpose. J Phytol 2/11 (2010) 13-24 
*Corresponding Author, Email: tyagi257@yahoo.in, Tel: 0416-228-4237  
1. Introduction to Angiogenesis 
The term “angiogenesis” was first used 
by Hertig in 1935 and refers to the formation 
of new blood vessels in the placenta (1) 
Angiogenesis is the process of generating 
new capillary blood vessels from already 
existing blood vessels which encompases the 
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multiple gene products expressed by various 
cell types and intergrated sequence of events. 
This uncontrolled process of new blood 
vessel growth from the pre-existing 
circulation network is an important 
pathogenic cause of tumor growth, many 
blinding ocular conditions and inflammatory 
diseases (2) Angiogenesis is a multistep 
process which includes degradation of the 
extracellular matrix (ECM) by matrix 
metalloproteinases (MMPs),endothelial cell 
proliferation, migration, and capillary tube 
formation. The whole process is tightly 
regulated by the balance between 
counteracting angiogenic stimulators and 
inhibitors (3,4).Angiogenesis can be 
characterized distinctly as hemangiogenesis 
(HA:blood neovascularisation) and 
Lymphangiogenesis (LA:Lymphatic 
neovascularisation), the later being an 
important initial step in tumor metastasis 
and transplant sensitization (5). During  
recent years, much has been learned about 
the stimulators and inhibitors of HA and LA 
and members of the vascular endothelial 
growth factor (VEGF) family emerged as 
prime mediators of both process (6). 
Increased vascularity likely allows for both 
an increase in tumor growth and a greater 
likelihood of hematogenous tumor migration. 
Thus,it has been hypothesized that inhibition 
of tumor angiogenesis will block tumor 
growth and reduce the potential for tumor 
metastasis. This hypothesis has led to an 
intensive effort to identify the molecular 
mechanisms of tumor angiogenesis to serve 
as the basic for novel anti-cancer therapy. 
VEGF is an endogenous mediator of 
angiogenesis (7,8).VEGF induces vascular 
growth in vivo and promotes endothelial cell 
responses that are important angiogenic 
responses such as increased proliferation, 
migration and protease 
production(7,9).Therefore ,inhibition of 
VEGF activity of disabling VEGF receptor 
function has been useful to inhibit tumor 
growth and metastasis in a variety of animal 
tumor models(10,11). 
In the early 1970s, Folkman and co-
workers hypothesized that tumor growth is 
angiogenesis-dependent and an anti-
angiogenic strategy might constitute a new 
therapeutic approach for the treatment of 
solid tumors (12,13). Now a days much effort  
has been directed toward discovering of new 
antiangiogenic agent.A variety of these 
agents such as 
Avastin(bevacizumab),thalidomide,TNP-470. 
Endostatin and angiostatin have been 
currently undergoing clinical evaluation for 
their efficacy in anti-angiogenic therapy 
(14,15). Moreover, Macugen (pepgaptanip 
sodium), a VEGF165-blocker,is the first anti-
angiogenic drug approved by FDA in 2005 
(16). Plants contain many active compounds. 
These are complex chemical cocktails with 
medicinal properties that modern 
pharmaceuticals cannot reproduce. A wide 
range of plants contains compounds with 
angiogenesis modulating properties 
 
Basic steps of angiogenesis 
Since Judah Folkman’s seminal article 
about tumor angiogenesis (17), numerous 
articles have been published about the 
various aspects of angiogenesis (18), refer 
also Angiogenesis: http://www.Kluwere 
online. com/issn/0969-6970/contents). There 
are at least ten sequential steps of 
angiogenesis (Figure 1)  Recent studies have 
shown the importance of leucocytes as 
providers of cytokines, chemokines and 
enzymes that are involved in angiogenesis. 
Angiogenesis stimulators and inhibitors 
target one or more of these steps. 
y Diseased or injured tissues produce 
and release angiogenic growth 
factors (proteins) that diffuse into the 
nearby tissues.  
y The angiogenic growth factors bind 
to specific receptors located on the 
endothelial cells (EC) of nearby 
preexisting blood vessels.  
y Once growth factors bind to their 
receptors, the endothelial cells 
become activated. Signals are sent 
from the cell's surface to the nucleus.  
y The endothelial cell's machinery 
begins to produce new molecules 
including enzymes. These enzymes 
dissolve tiny holes in the sheath-like 
covering (basement membrane) 
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surrounding all existing blood 
vessels.  
y The endothelial cells begin to divide 
(proliferate) and migrate out through 
the dissolved holes of the existing 
vessel towards the diseased tissue 
(tumor).  
y Specialized molecules called 
adhesion molecules called integrins 
(avb3, avb5) serve as grappling hooks 
to help pull the sprouting new blood 
vessel sprout forward.  
y Additional enzymes (matrix 
metalloproteinases or MMP) are 
produced to dissolve the tissue in 
front of the sprouting vessel tip in 
order to accommodate it. As the 
vessel extends, the tissue is remolded 
around the vessel.  
y Sprouting endothelial cells roll up to 
form a blood vessel tube.  
y Individual blood vessel tubes connect 
to form blood vessel loops that can 
circulate blood.  
y Finally, newly formed blood vessel 
tubes are stabilized by specialized 
muscle cells (smooth muscle cells, 
pericytes) that provide structural 
support. This starts the blood flow. 
 
Fig. 1: The ten sequential steps of angiogenesis 
 
 
 
 
 
 
 
 
 
 
 
Health and diseases of Angiogenesis 
In 1994, The Angiogenesis Foundation 
(http://www.angio.org) declared angiogenesis a 
‘common denominator’ in the most 
important diseases of society. In many 
serious diseases, the body loses control of 
angiogenesis. 
Normal Physiology 
In health, angiogenesis is under stringent 
control  by ab ‘angiogenic switch (Table1). 
Selected endogenous positive and negative 
regulators of angiogenesis) and this rarely 
occurs in adults except for embryogenesis, 
placentation, endometrial repair and wound 
healing (19,20). In the  latter case, formation 
of neovessels is necessary to sustain newly 
formed granulation tissues,in such a way 
that the ECs divide with a turnover rate of 
about 5 days, giving rise to a new 
microvascular network. During the 
menstrual cycle,however,angiogenesis 
occurs in copora lutea and endometrium 
with rapid growth and regression (21,22). 
Thus angiogenesis is normally in the 
quiescent state but is capable of both rapid 
activation and shutting down. 
 
Pathophysiology of Angiogenesis 
Excessive angiogenesis has been defined 
as a prominent pathological feature of many 
diseases such as cancer (Figure 2-Tumor 
angiogenesis and metastasis), rheumatoid 
arthritis, diabetic retinopathy, psoriasis, 
atherosclerosis, age related macular 
degeneration, endometriosis. The excessive 
angiogenesis occurs when diseased cells 
produce abnormally large amount of 
angiogenesis factors (e.g) VEGF-vascular 
endothelial growth factor, fibroblast growth 
factor (FGF)-2 and hepatocyte growth factors 
(23,24). During the early stage of 
tumorigenesis, tumors are usually not 
angiogenic, since oxygen can only diffuse to 
around 150-200 microns from capillaries, 
solid tumors can only grow to 1-2 mm 
autonomously at which stage they may exist 
for months or years without 
neovascualrisation (i.e. avascular phase). 
However, once tumor cells switch to the 
angiogenic phenotype (i.e) vascular phase), 
an extensive vascular network is constructed 
through sprouting or non-sprouting 
angiogenic mechanisms. The large amount of 
angiogenic factors, mainly VEGF secereted 
by tumor cells or activated ECS cells form a 
positive feedback on angiogenesis, leading to 
tumor growth and subsequent metastasis (25, 
26). 
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Figure 2-Tumor angiogenesis and metastasis 
 
 
 
 
 
 
 
 
 
 
 
 
 
A similar case has also been found in 
atherosclerosis, in which excessive 
angiogenesis enhance plaque growth in such 
a way to sustain perfusion, increase 
leukocyte exchange, deposition of 
proatherogenic plasma molecules and finally 
promote intraplaque hemorrhage (27). 
 
Insufficient Angiogenesis 
An insufficient amount of angiogenic 
stimulators and/or an excess of angiogenic 
inhibitors can tip the balance resulting 
inadequate or limited angiogenesis. 
Inadequate angiogenesis can also cause 
serious pathological outcomes such as stroke, 
Alzheimer disease, chronic wound, 
ulceration, ischemic coronary artery, critical 
limb ischemia and hypertension, hair loss 
(28,24). In diseases such as ischemic coronary 
artery or limb ischemia, the functional blood 
flow is partially lost in certain organs or 
limbs poor blood circulation greatly prolongs 
the recovery period or even results in 
morbidity or death. A similar phenomenon 
has been found in the aberrant wound repair 
in diabetic and gastric ulcer (29,30) 
excessive/abnormal disease table-
angiogenesis. 
 
Tumor angiogenesis as a therapeutic target 
Angiogenesis is considered a key step in 
tumour growth; invasion and metastasis. 
Tumours remain avasculat and latent for 
years: However tumor growth can be 
initiated by neoangiogenesis (25), the idea of 
blocking tumour growth by the attenuation 
of angiogenesis was put forward in the early 
70’s by Folkman (17). 
Since the discovery in the early 1970s that 
tumor progression is angiogenesis –
dependent, the concept of angiotherapy has 
been hypothesized as a therapeutic strategy 
(31). Ideally, this strategy could be used in 
the case of insufficient angiogenesis 
(e.g.heart ischemia) through stimulation of 
neovessels formation by introducing 
angiogenic stimulators. An over-burst of 
uncontrolled angiogenesis (e.g. tumours) 
could be treated using antiangiogenic  
inhibitors to shut down their formation of 
neovessels (32,33,34). After thirty years, this 
idea became a reality when the first-
generation anti-angiogenic drugs called 
Avastin (bevacizumab) and Macugen 
(Pegaptanip sodium) were approved by the 
Food and Drug Administration in the US in 
2004 and 2005 respectively for clinical 
application in cancer patients (35). 
Actually, a plethora of anti-angiogenic 
agents (e.g. TNP-470, thalidomide, 
Endostatin, and angiostatin) are being tested  
or undergoing  preclinical or clinical trials 
either alone or combination with 
conventional therapies (36,37,38). Most of 
these drugs target the ECs rather than tumor 
cells, thereby affecting different stages of 
angiogenesis. Therefore, they are less likely 
to cause bone marrow suppression, 
gastrointestinal symptoms or hair loss than 
conventional tumour therapies. 
During the last 12 years, considerable 
effort has been dedicated to identifying 
compounds that can be used to either 
prevent insurgence of primary tumours in 
subjects at high risk to develop cancer or 
prevent tumour relapse after surgical 
removal (39,40,41,42,43). 
Currently, ongoing clinical trials are 
focused to drugs that block matrix 
breakdown, drugs that inhibit endothelial 
cells directly, drugs that block activators of 
angiogenesis, drugs that inhibit endothelial-
specific  integrin/survival signaling as well 
as drugs with non-specific mechanism of 
action (based on National Cancer Institute, 
clinical database). 
On the other hand, the antiangiogenic 
effect of plant –derived natural compounds, 
Nanoparticle/Peptides/Flavonoids and 
chalcones/VEGE Isoforms/siRNA has been 
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studied intensively only for the last few 
years. 
2. Novel molecular targets of 
angiogenesis 
Eph receptors and ephrins 
Eph receptors are the largest family of 
receptor tyrosine kinase. These receptors and 
ephrin ligands were originally identified as 
neuronal-pathfinding molecules. Intriguingly, 
gene-targeting experiments in mice have  
identified the Eph B-Ephrin B system as  the 
crucial and rate-limiting determinant of 
arteriovenous differentiation during 
embryonic vascular development. Recent 
work has focused on the roles of the Eph-
ephrin system in controlling tumour and 
vascular functions during tumorigenesis and 
tumor progression (44). A better 
understanding of the Eph-ephrin system 
would lead to the selective targeting in 
antiangiogenic therapy of the molecules 
involved. 
Anti-angiogenic therapy is based on the 
normal genetic status of the target 
vasculature, and therefore is thought 
unlikely to lead to acquired resistance, 
however; recent data challenge this concept, 
using a xenograft murine model of human 
Wilms’ tumour. Huang et al. (45) 
characterised molecular changes in the 
vasculature during the apparent resumption 
of xenograft growth after initial inhibition by 
VEGF blockade, via ’metronome’ topotecan 
chemotherapy and combined agents. They 
showed that tumours that grow during anti-
angiogenic blockade develop as visible 
clusters surrounding remodeled vessels. 
These vessels display siginificant increases in 
diameter, are involved in the active 
proliferation of vascular mural cells and 
express PDGF-B,which enhances vascular 
integrity by stromal cells recruitment. In 
addition, remodeled vessels express ephrin 
B2, which is required for the proper 
assembly  of stromal cells into vasculature. 
Thus, Chronic anti-angiogenesis could lead 
to enhanced vascular stability, resulting in 
increased perfusion and recurrent tumour 
growth. If this phenomenon occurs in human 
cancers,targeting the EphB-ePhrinB system 
could be advantageous for treatment. 
 
Histone deacetylase 
Histone deacetylase (HDAC) is 
implicated in the alteration of chromatin 
assembly and tumorigenesis. Kim et al. (46) 
showed that HDAC is induced under 
hypoxia and elucidated a role for HDAC in 
the regulation of hypoxia –induced 
angiogenesis. The over expression of wild-
type HDAC1 down regulates p53 and VON 
Hippel-Lindau tumour suppressor gene 
expression, thus stimulating the angiogenesis 
of human ECs. 
TrichostatinA (TSA) is a potent and 
specific inhibitor of mammalian HDAC that 
upregulates p53 and von Hippel-Lindau 
expression and down regulates HiF-1Alpha 
and VEGF expression. It also blocks 
angiogenesis in vitro and in vivo, specifically 
hypoxia-induced angiogenesis in the Lewis 
lung carcinoma model. These results indicate 
that hypoxia enhances HDAC function and 
that HDAC is closely involved in 
angiogenesis by suppressing hypoxia-
responsive tumour suppressor genes. 
Using polymer–assisted solution–phase 
synthesis an array of HDAC inhibitors was 
generated. These compounds have 
considerable potential as anti-proliferative 
agents. Selected compounds inhibited 
human Ec proliferation and tube formation 
in an in vitro model of angiogenesis (47). 
Qian et al (48) recently reported that the 
hydroxamic acid derivative LBH589 induces 
a wide range of effects on ECs that  leads to 
inhibition of angiogenesis and 
phosphatidylcholine-3 tumour growth in vivo. 
Thus HDAC inhibitors should be considered 
as a therapeutic strategy for targeting both 
the tumour and the endothelial compartment 
and the clinical development of these agents 
in combination with other angiogenesis 
inhibitors is warranted. 
Nuclear receptors 
The structural differences in angiogenic 
factors and inhibitors are attributable to 
differences in receptor-binding affinities, 
pharmacology and mechanisms of action: for 
example, ginsenoside Rg1 and ginsenoside 
Rb1-The pharmacologically active 
components of Panax Ginseng. 
Protopanaxatriols such as Rg 1 and Re have 
pro-angiogenic effects (49, 50). 
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Whereas protopanaxtriols such as Rb1 
and Rg3 are antiangiogenic (51,52,53,54). 
Ginsenoside are triterpene saponins with 
subtle structural differences in the number of 
position of the sugar side-chain on a 
common steroidal backbone (Figure 4). 
Several studies indicate that the ginsenosides 
exert their effect by binding to nuclear 
hormone receptors(55,56,57). Indeed, recent 
findings demonstrate that ginsenosides can 
bind to nuclear receptors and exert both 
genomic and nongenomic effects on 
HUVECs. Recent studies show mapping of  
the signalling pathway of Rg1 that leads to 
the production of nitric oxide (K.W. Leung et 
al., unpublished report). Although 
ginsenosides such as Rg1, Rb1 are similar 
molecules, their minor structural differences 
might enable them to interact differentialy 
with nuclear receptors, leading to opposing 
effects on angiogenesis. Further 
investigations could lead to the development 
of specific ligands for the modulation of 
angiogenesis. 
 
Medicinal compound from plant sources 
In 1805, morphine was isolated from the 
opium poppy (Papaver somniferum) by the 
German Pharmacist Friedrich Serturner. 
Following the isolation of salicylic acid from 
the bark of the  Willow tree(Salix alba),Felix 
Hoffmann synthesized aspirin in 1897. 
Ephedrine was isolated from the Chinese 
herb Mahuang (Ephedra) in 1887 and became 
popular with American Physicians in 1924 
for its bronchodilating and decongestant 
properties. Sodium cromoglyate,first used in 
1968, is a Khellin derivatives that was  
isolated from Egyptian Khella seeds (Ammi 
visnaga) by Roger Altounyan. The anti-
malarial drug artemisinin was developed in 
1972 from the Chinese herb qinghao (sweet 
wormwood, Artemisia annua L.). These 
examples illustrates the rich history of plant 
–based medicinal compounds from 
medicinal plant for therapeutics model in 
human beings. 
Angiogenesis is the growth of neovessels 
from existing vaculature. Angiogenesis 
diseases result from new blood vessels 
growing either excessively (e.g. cancer 
diabetic retinopathy and psoriasis or 
insufficiently (e.g chronic wounds and 
ischaemic heart diseases). To date, the 
stimulation of angiogenesis using 
angiogenesis peptides has produced 
encouraging clinical results in treating 
coronary artery diseases. Blocking 
angiogenesis with antibodies/ peptides/ 
Nanopaticles/ siRNA/Flavonoids/chalcones 
of angiogenic factors or with enzyme 
inhibitors is effective for treating malignancy 
but there is room for improvement (Figure 4). 
Of particular relevance of this article is the 
fact that some of the plant derived 
compound and Peptide, siRNA, Flavonoids, 
chalcones, Ginsenosides, Nanoparticles 
antiangiogenic compounds/drugs (e.g. 
Taxol/ Camtothecin/ curcumin/ Ginestin/ 
Ginsenosides/ combreatastatin/ Traditional 
Chinese medicine) are useful for anti-
angiogenic therapy. Many herbs are used in 
the treatment of angiogenic diseases such as 
cancer, rheumatoid arthritis/chronic 
wound/heart diseases. Thus it is rational to 
explore these medicinal compounds from 
plant and Nano particles/ siRNA/ 
Flavonoids/ Chalcone/ Peptides/ VEGF 
isoform as a source of novel 
angiomodulators. In this article, we review 
plant based/ Nanoparticles, peptides, siRNA, 
Flavonoids, chalcone, Chinese traditional 
medicine etc angiotherapy and discuss the 
potential future of antiangiogenic therapeutic 
for treatment of angiogenic diseases. 
 
Fig. 4: Schematic overview of Ginsenoside Rg1 
mediated angiogenic action 
 
 
 
 
 
 
 
 
 
Angiogenic –modulating compounds from 
plants 
As highlighted by Szymkowski (58) and 
Lindsay (59), recent genomics focused drug 
discovery efforts have failed to produce the 
expected large number of compounds aimed 
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at “novel’ targets. The multifactorial nature 
of chronic diseases is probably the most 
significant problem in relation to target 
discovery. Different countries have distinct 
herbal traditions,each with their indigenous 
plants and unique practices.But one claim 
underlies them all that is the herbs have 
remarkable properties that make them 
potentially powerful medicines.In south 
Africa, Sutherlandia frutescens is being 
developed as  new treatment for HIV-AIDS. 
In Germany medicinal herbs are being 
broken down into their constituent parts and 
submitted to rigorous clinical trials. 
Plants contain many active compounds. 
These are complex chemical cocktails with 
medicinal properties that modern 
pharmaceuticals cannot reproduce. A wide 
range of plants contains compounds with 
angiogenesis modulating properties. 
 
3. Effect of plant derived compound 
on Tumor growth and angiogenesis 
Combretastatin 
Combretastatin is a  microtubule –
targeting agent found in the bark of the 
African bush willow tree (Combretum 
caffrum), identified in 1987 by Pettit et al. (60). 
Vincent et al (61) showed that  combretastatin 
A4 phosphate(CAP4). (Figure- 3) selectively 
targets ECs, but not smooth muscle cells and 
induces the regression of unstable nascent 
tumor neovessels in mice by rapidly 
disrupting the molecular engagement of the 
EC-specific junctional molecule vascular 
endothelial (VE) cadherin in vitro and in vivo. 
 
Figure- 3-Chemical structures of angiomodulators 
derived from medicinal plants and functional foods 
 
 
 
 
 
 
 
 
 
 
 
CAP4 increases EC permeability and 
inhibits EC migration and capillary tube 
formation, predominantly through the 
disruption of the VE-Cadherin-β –catenin-
Akt signaling pathway, resulting in rapid 
vascular collapse and tumor necrosis.CAP4 
synergises with low and nontoxic doses of 
neutralizing monoclonal antibodies to VE 
cadherin by blocking the assembly of 
neovessels, there by inhibiting tumour 
growth. 
CAP4 selectively induces the regression 
of unstable tumor neovessels, in part through 
the disruption of VE cadherin signaling. A 
combined treatment of anti-VE cadherin 
agents in conjuction with microtubule-
disrupting agents provides a novel 
synergistic strategy to disrupt assembly and 
induce regression of tumour neovessels 
selectively, with minimal toxicity and 
without affecting normal stabilized 
vasculature. 
 
Taxol 
In 1962, scientists at the National cancer 
Institute (http://www.cancer.gov/) determined 
that an extract from the bark of the pacific 
yew tree (Taxus brevifolia) possessed 
anticancer properties. In 1971,the active 
compound in this extract was identified by 
Wani et al.(62) as Taxol, a complex 
polyoxygenated diterpene (Figure- 3). Taxol 
kills proliferating cancer cells by disrupting 
their microtubule cytoskeletons (63,64,65). Of 
particular interest is the recent discovery that, 
at low picomolar  concentrations, Taxol is 
antiangiogenic, inhibiting VEGF 
production(66) and hypoxia-inducible factor 
(HIF)-α protein expression (67)The data 
support a clinical application of continuous 
ultra-low-dose Taxol to treat cancer(68). 
Fortunately, the needles and twigs of the 
Europena Yew tree(Taxus Baccata) contain 
10-deacetyl baccatin III,which is a close 
relative of Taxol.Because the needles are 
quickly replenished, harvesting large 
quantities has little effect on the population 
of yew trees. To produce sustainable 
source,10-deacetyl baccatinIII was chemically 
modified by Bristol Myers Scquibb 
Pharmaceuticals (http//:www.bms.com/ 
landing/dat/inde.html)and, in 1995, a semi-
synthetic version of Taxol-Paclitaxel-was 
made available to the public. 
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Camptothecin 
Using bioactivity –directed fractionation, 
Wall et al. (69) isolated Camptothecin 
(Figure- 3) from the Chinese tree Camtotheca 
acuminate. 
The use of Camptothecin as an anticancer 
agent languished for almost 15 years until its 
unique mode of action for killing tumour 
cells was determined. Canmptothecin traps 
topoisomerase I in complex with DNA ,thus 
preventing DNA  replication and resulting in 
the death of the cancer cell. This discovery  
rekindled the interest in developing 
analogues of Camptothecin  that are water 
soluble and retain their anticancer activity. In 
the mid -1990s, two camptothecin analogues, 
topotecan, and irinotecan, received FDA 
approval for use against ovarian, lung, breast 
and colon cancers (70,71). 
In 1999, Clemets et al.(72) showed that 
camptothecin and topotecan inhibit human 
EC growth in vitro in a non-cytotoxic manner 
and that this inhibition lasts >96 h after drug 
removal. They also showed that these two 
compounds,unlike the non-specific cytotoxic 
agent cisplatin, are effective as TNP-470 (73) 
at inhibition angiogenic growth in the in vivo  
disc angiogenesis model. Thus, in addition to 
their tumoricidal activities, camptothecins 
might have an indirect in vivo antitumour 
effect that is mediated through the inhibition 
of angiogenesis. 
 
Antiangiogenic effects of functional foods 
Food components can influence 
angiogenesis. On the one side this can 
contribute to pathological changes. For 
example (74,75) studies demonstrated that 
hypercholesterolemia enhances the synthesis 
of VEGF. It is thus conceivable that long term 
changes in lipid blood constituents,which 
may be the result of improper diet,can 
influence angiogenesis and add to the 
pathogenesis of cardiovascular diseases.The 
antiangiogenic functional foods provide a 
good strategy for the prevention of 
angiogenic diseases-(76,77). 
 
4. Conclusion 
Angiogenesis inhibitors are likely to 
change the face of medicine in the next 
decade. The chemopreventive agents that 
selectively interfere with particular 
biochemical alterations occurring in tumor 
cells or those acting on the highly specialized 
biology of endothelial cells during 
neovascularisation deserve special attention. 
Most of the currently available bioactive 
compounds, peptides, proteins, with 
antiangiogenic activities have been initially 
developed or used for experimental 
purposes, and have greatly contributed to 
the understanding and the modulation of the 
molecular mechanism of tumor angiogenesis. 
Several bioactive compounds, proteins 
(antibodies), peptides, siRNA, nanoparticles, 
flavonoids and chalcones etc. entered clinical 
testing as anti-angiogenic drugs, and a few of 
them are now approved for clinical use (e.g: 
Taxol, IFN-α, TNF, Bevacizumab). 
The discoveries of Bioactive compounds 
such as Taxol, camptothecin and 
combrestastatin, Ginsenosides, sinomenine, 
and triptolide from plants are important 
milestone in the history of anticancer drugs. 
These examples of synthetic chemistry 
leading to more-efficacious analogues and 
their subsequent clinical use illustrate the 
power of combining medicinal chemistry 
and pharmacology. 
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